IDiyas

For the Inventor, By the Inventor

Quincy, MA, United States of America

Thomas H Graham

USPTO Granted Patents = 30 

 

 

Average Co-Inventor Count = 6.8

ph-index = 3

Forward Citations = 30(Granted Patents)


Location History:

  • Scotch Plains, NJ (US) (2013 - 2018)
  • Quingy, MA (US) (2019)
  • Quincy, MA (US) (2018 - 2022)
  • Somerville, MA (US) (2021 - 2024)

Company Filing History:

goldMedal30 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
30 patents (USPTO):
1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),
2. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),
3. 12297208 - Small molecule inhibitors of KRAS G12C mutant (2025-05-13),
4. 12291538 - Small molecule inhibitors of KRAS G12C mutant (2025-05-06),
5. 12263171 - 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2025-04-01),
6. 12060357 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2024-08-13),
7. 11697657 - Small molecule inhibitors of KRAS G12C mutant (2023-07-11),
8. 11358711 - Tetracyclic heterocycle compounds useful as HIV integrase inhibitors (2022-06-14),
9. 11312719 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2022-04-26),
10. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),
11. 11104690 - Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2021-08-31),
12. 10947222 - Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2021-03-16),
13. 10934312 - Tricyclic heterocycle compounds useful as HIV integrase inhibitors (2021-03-02),
14. 10829499 - Tetracyclic heterocycle compounds useful as HIV integrase inhibitors (2020-11-10),
15. 10624912 - Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors (2020-04-21),

Title: Innovations and Contributions of Thomas H. Graham in Cancer Therapeutics

Introduction: Thomas H. Graham, based in Quincy, MA, is a prominent inventor in the field of pharmaceuticals with a remarkable portfolio of 28 patents. His work primarily focuses on the development of small molecule inhibitors designed to target specific mutants of proteins involved in cancer progression.

Latest Patents: Among his latest innovations is a patent for small molecule inhibitors of the KRAS G12C mutant. This patent includes compounds of Formula (I) or their pharmaceutically acceptable salts, which have the potential to inhibit the G12C mutant of the Kirsten rat sarcoma (KRAS) protein. These compounds are anticipated to serve as therapeutic agents in cancer treatment. The patent also encompasses pharmaceutical compositions containing these compounds, in addition to methods for utilizing these inhibitors for cancer therapy and prophylaxis.

Career Highlights: Thomas H. Graham’s career is marked by his significant advancements in drug discovery and development while working at Merck Sharp & Dohme Corporation. His dedication to innovation has led to numerous breakthroughs in cancer therapeutics, particularly through his focus on molecular targeting.

Collaborations: Throughout his career, Thomas has collaborated with esteemed colleagues, including Tao Yu and Sherman Tim Waddell. These partnerships have fostered an environment of creativity and scientific exploration, contributing to the success of his projects and the enhancement of cancer treatment options.

Conclusion: Thomas H. Graham's contributions to the field of cancer therapeutics through his patents and collaborative work underscore his impact on modern medicine. His innovations, particularly in developing small molecule inhibitors for the KRAS G12C mutant, continue to pave the way for effective cancer treatments, showcasing his commitment to advancing healthcare through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…